Drug Type Cytokines |
Synonyms LTC 004, LTC-004 |
Target |
Action agonists |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists), IL15R agonists(Interleukin-15 receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Sarcoma | Phase 2 | - | 26 Apr 2024 | |
Sarcoma | Phase 2 | China | 26 Apr 2024 | |
Metastatic Colorectal Carcinoma | Phase 2 | China | 24 Apr 2024 | |
Soft Tissue Sarcoma | Phase 1 | China | 19 Feb 2024 | |
Lymphoma | Phase 1 | China | 08 Dec 2022 | |
Advanced cancer | Phase 1 | - | 01 Dec 2022 |
NCT05666635 (ASCO2024) Manual | Phase 1 | 17 | mqgvugznvg(eexlbmdlgk) = LTC004 generally well tolerated and no dose-limiting toxicities (DLTs) up to and including 360 µg/kg was observed. meagojryrm (jhmejmhwiu ) View more | Positive | 29 May 2024 |